The clinical significance of osteopontin on the cardiovascular outcomes in patients with stable coronary artery disease

Kei-Ip Cheong; Hsin-Bang Leu; Chau-Chung Wu; Wei-Hsian Yin; Ji-Hung Wang; Tsung-Hsien Lin; Wei-Kung Tseng; Kuan-Cheng Chang; Shu-Hsun Chu; Hung-I Yeh; Jaw-Wen Chen; Yen-Wen Wu; National Taiwan Biosignature Research Investigators

doi:10.1016/j.jfma.2022.11.011

The clinical significance of osteopontin on the cardiovascular outcomes in patients with stable coronary artery disease

J Formos Med Assoc. 2023 Apr;122(4):328-337. doi: 10.1016/j.jfma.2022.11.011. Epub 2022 Dec 7.

Authors

Affiliations

¹ Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan; College of General Education, Chihlee University of Technology, New Taipei City, Taiwan.
² Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang Ming Chao Tung University, Taipei, Taiwan.
³ University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; Graduate Institute of Medical Education & Bioethics, College of Medicine, National Taiwan University, Taipei, Taiwan.
⁴ Division of Cardiology, Heart Center, Cheng Hsin General Hospital, Taipei, Taiwan.
⁵ Division of Cardiology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
⁶ Kaohsiung Medical University Hospital and Kaohsiung Medical University, Kaohsiung, Taiwan.
⁷ Division of Cardiology, Department of Internal Medicine, E-Da Hospital, Kaohsiung, Taiwan.
⁸ Division of Cardiovascular Medicine, Department of Medicine, China Medical University Hospital, Taichung 404332, Taiwan; Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404333, Taiwan.
⁹ National Taiwan University, Taipei, Taiwan.
¹⁰ Department of Internal Medicine and Medical Research, Mackay Memorial Hospital, Taipei, Taiwan; Department of Medicine, Mackay Medical College, New Taipei City, Taiwan.
¹¹ Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang Ming Chao Tung University, Taipei, Taiwan; Healthcare and Services Center, Taipei Veterans General Hospital, Taipei, Taiwan; Cardiovascular Research Center, National Yang Ming Chao Tung University, Taipei, Taiwan; Institute of Pharmacology, National Yang Ming Chao Tung University, Taipei, Taiwan. Electronic address: chen@vghtpe.gov.tw.
¹² Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan; School of Medicine, National Yang Ming Chao Tung University, Taipei, Taiwan; Graduate Institute of Medicine, Yuan Ze University, Taoyuan, Taiwan. Electronic address: wuyw0502@gmail.com.

PMID: 36494313
DOI: 10.1016/j.jfma.2022.11.011

Abstract

Background: Osteopontin (OPN) is a noncollagenous matricellular protein which is mainly present in bone matrix. A high OPN level has been associated with heart failure and acute coronary syndrome, however data on patients with chronic coronary syndrome (CCS) are lacking. The present study aimed to evaluate the association between OPN and the prognosis of Taiwanese patients with CCS.

Methods: We enrolled participants from the Biosignature Registry, a nationwide prospective cohort study conducted at nine different medical centers throughout Taiwan. The inclusion criteria were participants who had received successful percutaneous coronary intervention at least once previously, and stable under medical therapy for at least 1 month before enrollment. They were followed for at least 72 months. Logistic regression and Cox proportional hazard model were used to investigate the association between OPN and clinical outcomes. The outcomes of this study were the first occurrence of hard cardiovascular events and composite cardiovascular outcomes including cardiovascular mortality, revascularization, hospitalization for acute myocardial infarction (AMI) or heart failure.

Results: A total of 666 patients with both hs-CRP and osteopontin measurements were enrolled and followed for 72 months. OPN was correlated positively with AMI-related hospitalization, where the highest tertile (Tertile 3) of baseline OPN had the highest risk of AMI-related hospitalization, which remained significant after multivariate adjustments (HR 3.20, p = 0.017). In contrast, combining OPN and hs-CRP did not improve the prediction of CV outcomes.

Conclusion: OPN may be a potentially valuable biomarker in predicting CV outcomes. During 6 years of follow-up period, an OPN level >4810 pg/ml was associated with a significantly higher incidence of AMI-related hospitalization in CCS patients who received successful PCI before the enrollment.

Keywords: Acute myocardial infarction; Biomarker; Cardiovascular outcome; Chronic coronary syndrome; Osteopontin.

MeSH terms

C-Reactive Protein / analysis
Clinical Relevance
Coronary Artery Disease* / therapy
Heart Failure*
Humans
Myocardial Infarction* / therapy
Osteopontin
Percutaneous Coronary Intervention*
Prospective Studies
Risk Factors
Treatment Outcome

Substances

Osteopontin
C-Reactive Protein